GSK to rush out breast cancer treatment after trials success

GlaxoSmithKline's experimental breast cancer treatment, Tykerb, has proved so successful in drug trials it will be made available to patients in late stages of the disease, even before it gets the nod from regulators.

Europe's largest drug maker is set to dominate the world's biggest cancer conference in Atlanta today with data on Tykerb. Unlike Roche's $1.8bn-a-year drug, Herceptin, Tykerb can reduce the size of brain tumours caused by breast cancer, a problem for 30 to 40 per cent of women with the aggressive, recurring form of the cancer. The data also demonstrates that Tykerb works on patients where Herceptin has failed, and shows a significant increase in life expectancy. As a pill, Tykerb is also more convenient than Herceptin, which has to be injected.

US regulators have allowed GSK to offer Tykerb to doctors who wish to treat women suffering from advanced breast cancer, before regulatory approval for full-scale marketing of the pill, which is expected sometime next year. In the UK, patients could also be treated with Tykerb on "compassionate" grounds.

Final-stage clinical trials have shown that Tykerb, when given to women in combination with the chemotherapy drug Xeloda, slows the development of the cancer, nearly doubling the length of time patients live without the disease. The trials were stopped ahead of schedule last month because Tykerb worked so well.

But GSK still has a long way to go. Clinical trials to test Tykerb on early-stage breast cancer will take several years. Meanwhile, Herceptin was approved by the European Commission this week to fight early-stage breast cancer, and is likely to be cleared in the UK soon. That promises relief to many sufferers, some of whom have fought to get the drug on the NHS, at an estimated cost of £20,000 per patient a year.

Tykerb is believed to be far cheaper than Herceptin once it comes on to the market.

The Swiss pharmaceuticals giant Roche is developing combination treatments that could rival Tykerb. More than 1 million women are newly diagnosed with breast cancer every year worldwide - about 40,000 in the UK.

GSK's cancer business, until now relatively small, is likely to be transformed next year with the launch of Tykerb and other blockbuster drugs, such as the cervical cancer vaccine Cervarix and Eltrombopag, a blood-clotting agent in the treatment of breast cancer. The group is also developing a lung cancer vaccine that would stop the disease spreading.

The drug maker has emerged as one of the front-runners in the $15bn-plus bidding for the consumer healthcare arm of its US rival Pfizer, along with Johnson & Johnson, Reckitt Benckiser and Wyeth. The deal would transform GSK into the world's largest maker of non-prescription drugs. Second-round bids have to be in by Tuesday.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Graduate Recruitment Resourcer

£20000 per annum + commission: SThree: Sthree have an exciting opportunity for...

Recruitment Genius: Telesales Executive - OTE £32,000+

£18000 - £32000 per annum: Recruitment Genius: A Telesales Executive is requir...

Ashdown Group: Marketing Manager - B2B, Corporate - City, London

£45000 - £50000 per annum + benefits : Ashdown Group: A highly successful, glo...

Neil Pavier: Commercial Analyst

£50,000 - £55,000: Neil Pavier: Are you a professionally qualified commercial ...

Day In a Page

General Election 2015: The masterminds behind the scenes

The masterminds behind the election

How do you get your party leader to embrace a message and then stick to it? By employing these people
Machine Gun America: The amusement park where teenagers go to shoot a huge range of automatic weapons

Machine Gun America

The amusement park where teenagers go to shoot a huge range of automatic weapons
The ethics of pet food: Why are we are so selective in how we show animals our love?

The ethics of pet food

Why are we are so selective in how we show animals our love?
How Tansy Davies turned 9/11 into her opera 'Between Worlds'

How a composer turned 9/11 into her opera 'Between Worlds'

Tansy Davies makes her operatic debut with a work about the attack on the Twin Towers. Despite the topic, she says it is a life-affirming piece
11 best bedside tables

11 best bedside tables

It could be the first thing you see in the morning, so make it work for you. We find night stands, tables and cabinets to wake up to
Italy vs England player ratings: Did Andros Townsend's goal see him beat Harry Kane and Wayne Rooney to top marks?

Italy vs England player ratings

Did Townsend's goal see him beat Kane and Rooney to top marks?
Danny Higginbotham: An underdog's tale of making the most of it

An underdog's tale of making the most of it

Danny Higginbotham on being let go by Manchester United, annoying Gordon Strachan, utilising his talents to the full at Stoke and plunging into the world of analysis
Audley Harrison's abusers forget the debt he's due, but Errol Christie will always remember what he owes the police

Steve Bunce: Inside Boxing

Audley Harrison's abusers forget the debt he's due, but Errol Christie will always remember what he owes the police
No postcode? No vote

Floating voters

How living on a houseboat meant I didn't officially 'exist'
Louis Theroux's affable Englishman routine begins to wear thin

By Reason of Insanity

Louis Theroux's affable Englishman routine begins to wear thin
Power dressing is back – but no shoulderpads!

Power dressing is back

But banish all thoughts of Eighties shoulderpads
Spanish stone-age cave paintings 'under threat' after being re-opened to the public

Spanish stone-age cave paintings in Altamira 'under threat'

Caves were re-opened to the public
'I was the bookies’ favourite to be first to leave the Cabinet'

Vince Cable interview

'I was the bookies’ favourite to be first to leave the Cabinet'
Election 2015: How many of the Government's coalition agreement promises have been kept?

Promises, promises

But how many coalition agreement pledges have been kept?
The Gaza fisherman who built his own reef - and was shot dead there by an Israeli gunboat

The death of a Gaza fisherman

He built his own reef, and was fatally shot there by an Israeli gunboat